Cohance Lifesciences Invests USD 10 mn in cGMP Bioconjugation Suite at NJ Bio to Accelerate ADC Innovation

Cohance Lifesciences, a leading global Contract Research, Development & Manufacturing Organization (CRDMO), announced a strategic investment of USD 10 million to expand cGMP bioconjugation capabilities at its U.S based subsidiary, NJ Bio. This investment advances Cohance’s global expansion in niche technology-led modalities, enhancing its ability to support innovators from early development through late-phase clinical supply. The new suite, designed to handle high-potent drug substances, will have the flexibility to manufacture up to 2 kg of ADCs, sufficient for clinical requirements once the program transitions to cGMP production in the expanded facility. NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline and is in advanced discussions with three to four additional customers whose ADC programs are expected to transition to CGMP manufacturing in alignment with the commissioning of the expanded suite.